SLDB Live signaler | Maksimer profitt med Getagraph.com

SELG 107835 min ago

@ $8.00

Utstedt: 14 feb 2024 @ 15:30

Avkastning: 12.25%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: 4.30 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	189 872
Gjennomsnittsvolum	267 917
Markedsverdi	339.06M
EPS	$0 ( 2024-03-28 )
Neste inntjeningsdato	( $-0.570 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.860
ATR14	$0.0310 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Smith Ian F	Buy	3 256	Common Stock
2024-04-03	Smith Ian F	Sell	3 256	Restricted Stock Units
2024-02-13	Hanrahan Jessie	Buy	65 000	Employee Stock Option (Right to Buy)
2024-02-13	Hanrahan Jessie	Buy	32 500	Restricted Stock Units
2024-02-13	Cumbo Alexander	Buy	240 250	Employee Stock Option (Right to Buy)

INSIDER POWER
95.48
Last 96 transactions
Buy: 8 088 873 \| Sell: 207 617

Volum Korrelasjon

Lang: 0.17 (neutral)

Kort: 0.82 (strong)

Signal:(65.816) Same movement expected

Solid Biosciences Inc Korrelasjon

10 Mest positive korrelasjoner
CIZN	0.814

10 Mest negative korrelasjoner
CATB	-0.823

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Solid Biosciences Inc Korrelasjon - Valuta/Råvare

0.02
( neutral )

-0.26
( neutral )

0.00
( neutral )

0.42
( neutral )

0.86
( strong )

0.60
( weak )

Solid Biosciences Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2023
Omsetning:	$0
Bruttogevinst:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2022
Omsetning:	$8.09M
Bruttogevinst:	$5.69M (70.25 %)
EPS:	$-7.70

FY	2021
Omsetning:	$13.62M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-10.14

Financial Reports:

No articles found.

Solid Biosciences Inc

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.